Also trades as: ROIVW (NASDAQ) · $vol 0M
ROIV NASDAQ
Roivant Sciences Ltd.
1W: +4.6%
1M: -1.2%
3M: +11.2%
YTD: +66.6%
1Y: +100.5%
3Y: +278.3%
5Y: +482.8%
$36.54
+0.49 (+1.36%)
Weekly Expected Move ±5.5%
$32
$34
$36
$39
$41
Credit Risk of going bust: lower than 90% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.01 (down more than 99.9%), Roivant Sciences Ltd. would be worth roughly what it owes.
Total debt $107.2M against a stock market value of $26.39B.
Distance to default 13.63 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $53.6M (short-term plus half of long-term), stock volatility 45.2%; Altman Z'' 16.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $107.2M against a stock market value of $26.39B.
Distance to default 13.63 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $53.6M (short-term plus half of long-term), stock volatility 45.2%; Altman Z'' 16.14. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
22 relationships19
As Filer
counterparties named
3
As Counterparty
mentioned by others
4
Rel. Types
2021-08-02
Earliest Filing
2026-03-23
Latest Filing
partner: 11
investor: 4
acquirer: 3
target: 1
Counterparties (Filed by ROIV)
19 relationshipsCompanies named in ROIV's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Genevant Sciences GmbH | — | partner | Subsidiary of Roivant Sciences Ltd. involved in patent litigation settlement. | 2026-03-23 | View |
| Arbutus Biopharma Corp. | ABUS | partner | Partner in patent litigation settlement with Roivant Sciences Ltd. | 2026-03-23 | View |
| Moderna, Inc. | MRNA | partner | Counterparty in patent litigation settlement regarding lipid nanoparticle technology. | 2026-03-23 | View |
| ModernaTx, Inc. | MRNA | partner | Entity involved in patent litigation settlement with Roivant Sciences Ltd. | 2026-03-23 | View |
| Genevant Sciences GmbH | — | partner | Subsidiary of Roivant Sciences Ltd. involved in patent litigation settlement. | 2026-03-03 | View |
| Arbutus Biopharma Corp. | ABUS | partner | Partner in patent litigation settlement with Genevant Sciences GmbH. | 2026-03-03 | View |
| Moderna, Inc. | MRNA | partner | Pharmaceutical company involved in patent litigation settlement and licensing agreement. | 2026-03-03 | View |
| ModernaTx, Inc. | MRNA | partner | Entity involved in patent litigation settlement with Genevant/Arbutus. | 2026-03-03 | View |
| Dermavant Sciences Ltd. | — | target | Target company in a merger agreement with Organon. | 2024-09-23 | View |
| Organon & Co. | OGN | acquirer | Acquiring company in a merger agreement with Dermavant. | 2024-09-23 | View |
| Organon Bermuda Ltd. | OGN | partner | Wholly owned subsidiary of Organon participating in the merger. | 2024-09-23 | View |
| Dermavant Sciences GmbH | — | partner | Entity party to the Revenue Interest Purchase and Sale Agreement. | 2024-09-23 | View |
| XYQ Luxco S.A.R.L. | — | partner | Entity party to the Revenue Interest Purchase and Sale Agreement. | 2024-09-23 | View |
| NovaQuest Co-Investment Funds XVII, L.P. | — | investor | Investor party to the Revenue Interest Purchase and Sale Agreement. | 2024-09-23 | View |
| NovaQuest Co-Investment Fund VIII, L.P. | — | investor | Investor party to the Funding Agreement. | 2024-09-23 | View |
| NovaQuest Capital Management, LLC | — | investor | Affiliate of NovaQuest Co-Investment Fund XVII, L.P. | 2024-05-30 | View |
| Marathon Asset Management, L.P. | — | investor | Affiliate of MAM Tapir Lender, LLC. | 2024-05-30 | View |
| Pfizer Inc. | PFE | acquirer | Acquired Telavant Holdings, Inc. for approximately $7.1 billion in cash. | 2023-12-14 | View |
| Roche Holdings, Inc. | — | acquirer | Joint acquirer of Telavant Holdings, Inc. with Pfizer Inc. for approximately $7.1 billion in cash. | 2023-12-14 | View |
Mentioned As Counterparty
3 mentionsOther companies that named ROIV in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| IMVT Immunovant, Inc. | investor | Institutional accredited investor participating in the private placement of common stock. | 2025-01-13 | View |
| OGN Organon & Co. | partner | Representative of Dermavant securityholders in the Merger Agreement. | 2024-09-23 | View |
| IMVT Immunovant, Inc. | investor | Roivant agreed to purchase 17,021,276 shares of Immunovant common stock for $200 million. | 2021-08-02 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-21 | Regulation FD; Exhibits | View | |
| 2026-09-18 | Shareholder Vote; Exhibits | View | |
| 2026-09-08 | Regulation FD; Exhibits | View | |
| 2026-08-28 | Other Events; Exhibits | View | |
| 2026-08-27 | Regulation FD; Exhibits | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-05-20 | Earnings Release; Exhibits | View | |
| 2026-04-02 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-03-23 | Material Agreement; Exhibits | Agreement | View |
| 2026-03-03 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-03-03 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Other Events; Financial Statemen | Agreement | View |
| 2026-02-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-17 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-11 | Submission of Matters to a Vote of Security Holders; Financial Statements and Exhibits | View | |
| 2025-09-03 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-25 | Other Events; Financial Statements and Exhibits | View | |
| 2025-05-29 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR